ABEO: Steady ZEVASKYN launch growth, expanding access, and strong pipeline signal major long-term potential
ZEVASKYN’s U.S. launch is progressing with expanding treatment center access, robust insurance coverage, and positive patient outcomes. Manufacturing capacity and foundational growth are scaling, with a $4B+ addressable market and additional pipeline and royalty opportunities ahead.Based on Abeona…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.